The impact of antiplatelet and anticoagulant therapies on gastrointestinal symptoms in patients with atrial fibrillation: A systematic review;Impact des traitements antiplaquettaires et anticoagulants sur les symptômes gastro-intestinaux chez les patients atteints de fibrillation auriculaire: Une revue systématique

Annals of Pharmacotherapy

Volumn 46, Issue 9, 2012, Pages 1220-1231

  Sobieraj, Diana M ^a   White, C Michael ^a   Alikhanov, Sabina ^a   Winkler, Sara ^a   Mediouni, Malek ^a   Kluger, Jeffrey ^b   Coleman, Craig I ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Atrial fibrillation; Dyspepsia; Gastrointestinal symptoms; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; ATECEGATRAN METOXIL; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTICLE; DIARRHEA; DYSPEPSIA; GASTRITIS; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; MEDLINE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; SYSTEMATIC REVIEW; THROMBOSIS; VOMITING;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DIARRHEA; DYSPEPSIA; GASTROINTESTINAL DISEASES; HUMANS; NAUSEA; PLATELET AGGREGATION INHIBITORS;

EID: 84865857895     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R064     Document Type: Article

References (23)

1. You JJ, Singer DE, Howard PA, et al.; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 suppl):e531S-75S.
2. Chisholm-Burns MA, Spivey CA. Pharmacoadherence: a new term for a significant problem. Am J Health Syst Pharm 2008;65:661-7.
3. Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Preference and Adherence 2010;4:51-60.
4. Richter JE. Gastroesophageal reflux disease in the older patient: presentation, treatment, and complication. Am J Gastroenterol 2000;95:368-73.
5. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
6. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.
7. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
8. Hiroshi Sato, Kinji Ishikawa, Akira Kitabatake, et al., on behalf of the Japan Atrial Fibrillation Stroke Trial (JAST) Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006;37:447-51.
9. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-9.
10. Gulløv AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-21.
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
12. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-26.
13. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-8.
14. Albers GW, Diener HC, Frison L, et al. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8.
15. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009;30:2897-907.
16. The Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation: final results. Circulation 1991;84:527-39.
17. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF-II: a doseguiding, tolerability and safety study. J Am Coll Cardiol 2003;41: 1445-51.
18. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. Am Heart J 1999;138:137-43.
19. Rash A, Downes T, Portner R, et al. A randomized controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007;36:151-6.
20. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-16.
21. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
22. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
23. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;11:17.